Literature DB >> 10599723

Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.

S Heger1, C J Partsch, W G Sippell.   

Abstract

A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH). The aim of this prospective, multicentric study was the evaluation of the benefits, side-effects, and long term outcome of depot GnRH agonist therapy. We investigated 50 young women (mean +/- SD age, 16.7+/-2.6 yr; range, 12.9-23.4 yr) at FH. They received depot triptorelin over a period of 4.4+/-2.1 yr (range, 1.0-9.7 yr). Target height (TH) and predicted adult height (PAH) at the start of treatment were 163.6+/-6.2 and 154.9+/-9.6 cm, respectively (P < 0.05). FH was 160.6+/-8.0 cm (FH vs. TH, P = NS; FH vs. PAH, P < 0.05). Young patients showed the highest height gain (FH minus initial PAH). Seventy-eight percent of all patients reached a FH within their TH range. Even in young patients and those with an unfavorable initial PAH below the TH range, 60% reached a FH within their individual TH range. Standardized bone mineral density and standardized bone mineral density SD score investigated by dual energy x-ray absorptiometry of the lumbar spine (L1-L4) were 1040.9+/-124.2 mg/cm2 and 0.0+/-1.0; those of the femoral neck were 902.2+/-115.4 mg/cm2 and 0.2+/-1.0, respectively. The SD score of the ratio of sitting height over lower leg length was normal (0.3+/-1.2). Body mass index SD scores at pretreatment, at the end of treatment, and at FH were not significantly different (2.0+/-2.0, 2.0+/-2.0, and 1.7+/-2.2, respectively). Menarche or remenarche started at age 12.3+/-1.4 yr (range, 9.3-15.8 yr) in all patients. In conclusion, long term depot GnRH agonist treatment of CPP girls preserved genetic height potential and improved FH significantly combined with normal body proportions. No negative effect on bone mineral density and reproductive function was seen. Treatment neither caused nor aggravated obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10599723     DOI: 10.1210/jcem.84.12.6203

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Follow-up of children and young adults after GnRH-agonist therapy or central precocious puberty.

Authors:  P P Feuillan; J V Jones; K Barnes; K O Klein; G B Cutler
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.

Authors:  Simone Kapteijns-van Kordelaar; Kees Noordam; Barto Otten; Joop van den Bergh
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

Review 3.  Disorders of pubertal development.

Authors:  Jürgen Brämswig; Angelika Dübbers
Journal:  Dtsch Arztebl Int       Date:  2009-04-24       Impact factor: 5.594

4.  Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIE-SIEDP-ONIG.

Authors:  A D Fisher; J Ristori; E Bandini; S Giordano; M Mosconi; E A Jannini; N A Greggio; A Godano; C Manieri; C Meriggiola; V Ricca; D Dettore; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-05-27       Impact factor: 4.256

5.  Growth in precocious puberty.

Authors:  Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

6.  Resumption of puberty in girls and boys following removal of the histrelin implant.

Authors:  Marisa M Fisher; Deborah Lemay; Erica A Eugster
Journal:  J Pediatr       Date:  2014-01-14       Impact factor: 4.406

Review 7.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.

Authors:  Hae Sang Lee; Jong Seo Yoon; Jung Ki Roh; Jin Soon Hwang
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

9.  An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D.

Authors:  A Kaya; A Cayir; M I Turan; B Ozkan
Journal:  West Indian Med J       Date:  2015-01-21       Impact factor: 0.171

10.  Central precocious puberty due to hypothalamic hamartoma in a 7-month-old infant girl.

Authors:  I H Rousso; M Kourti; D Papandreou; A Tragiannidis; F Athanasiadou
Journal:  Eur J Pediatr       Date:  2007-06-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.